Hexagon Nutrition Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Latest quarter profit grew 1166.6% YoY, showing strong momentum
- Institutional investors have been accumulating - FII+DII up 6.7pp
- Company maintains a comfortable, low leverage position
CONS
- A large part of profit comes from other income (45.3% of PBT)
- Company has a low return on capital employed of 10.4%
- Contingent liabilities are large at 55.3% of net worth
- Recurring exceptional / one-off items are inflating headline profit
- Company has delivered a poor profit growth of 9.4% over past five years
- Operating margins have contracted to 10.3% from 13.4%
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| HEXAGON | 68.30 | 22.13 | 839.53 | 0.00 | 8.07 | — | 104.31 | -2.08 | 17.37 | 11.25 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| 83 | 63 | 98 | 101 | |
| 75 | 57 | 84 | 91 | |
| Operating Profit | 9 | 6 | 14 | 10 |
| OPM % | 10.28% | 9.27% | 14.22% | 10.07% |
| 2 | 2 | 6 | 3 | |
| Interest | 1 | 0 | 1 | 1 |
| Depreciation | 1 | 1 | 2 | 1 |
| Profit before Tax | 9 | 8 | 18 | 13 |
| Tax % | 25.56% | 25.26% | 25.11% | 25.72% |
| Net Profit | 7 | 6 | 14 | 10 |
| 0.60 | 0.54 | 1.23 | 0.82 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 68 | 70 | 92 | 119 | 99 | 87 | 107 | 114 | 132 | 157 | 347 | |
| 61 | 68 | 97 | 108 | 88 | 80 | 94 | 115 | 120 | 141 | 308 | |
| Operating Profit | 7 | 3 | -5 | 11 | 10 | 7 | 13 | -1 | 13 | 16 | 39 |
| OPM % | 10.10% | 3.62% | -5.23% | 9.39% | 10.60% | 8.45% | 12.02% | -0.80% | 9.59% | 10.31% | 11.15% |
| 0 | 1 | 1 | 3 | 1 | 3 | 2 | 2 | 6 | 7 | 14 | |
| Interest | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 4 | 2 |
| Depreciation | 3 | 4 | 4 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 6 |
| Profit before Tax | 1 | -2 | -9 | 9 | 8 | 7 | 13 | -3 | 14 | 16 | 48 |
| Tax % | 120.46% | 26.50% | 22.44% | 26.14% | 6.81% | 24.08% | 29.03% | -17.83% | 25.20% | 26.70% | 25.38% |
| Net Profit | -0 | -1 | -7 | 6 | 7 | 6 | 9 | -3 | 10 | 12 | 36 |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.60 | 0.46 | 0.73 | -0.25 | 0.95 | 1.05 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 29.14% | 18.55% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 12%
- 5 Years:
- 10%
- 3 Years:
- 14%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 24%
- 5 Years:
- 9%
- 3 Years:
- 9%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- 10 Years:
- 7%
- 5 Years:
- 12%
- 3 Years:
- 10%
- Last Year:
- 18%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | |
| 17 | 29 | 22 | 27 | 35 | 37 | 44 | 39 | 49 | 56 | |
| 16 | 15 | 25 | 15 | 13 | 11 | 21 | 26 | 40 | 35 | |
| Trade Payables | 11 | 15 | 17 | 18 | 14 | 12 | 15 | 27 | 15 | 9 |
| 8 | 22 | 19 | 22 | 22 | 22 | 24 | 22 | 22 | 24 | |
| Total Liabilities | 64 | 91 | 94 | 93 | 95 | 93 | 115 | 125 | 137 | 135 |
| 28 | 26 | 25 | 24 | 21 | 20 | 20 | 22 | 25 | 28 | |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 0 |
| 7 | 12 | 7 | 12 | 12 | 16 | 20 | 16 | 8 | 14 | |
| 10 | 17 | 23 | 15 | 17 | 19 | 27 | 27 | 27 | 29 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24 | 22 | |
| Cash & Bank | 1 | 10 | 2 | 2 | 7 | 7 | 5 | 6 | 5 | 4 |
| 18 | 26 | 38 | 41 | 38 | 31 | 41 | 53 | 46 | 37 | |
| Total Assets | 64 | 91 | 94 | 93 | 95 | 93 | 115 | 125 | 137 | 135 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -10 | -21 | 0 | 12 | 6 | 4 | 8 | -2 | 12 | |
| Cash from Investing | -0 | -6 | 3 | 0 | -1 | -2 | -11 | -8 | -8 | 2 |
| Cash from Financing | 0 | 25 | 10 | 0 | -5 | -4 | 7 | 3 | 11 | -13 |
| -1 | 8 | -8 | 0 | 5 | -1 | -3 | 2 | 1 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-01 - Hexagon Nutrition Limited has informed the Exchange about General Updates
2026-09-01 - Hexagon Nutrition Limited has informed the Exchange about General Updates
2026-09-01 - Hexagon Nutrition Limited has informed the Exchange about Copy of Newspaper Publication - Information regarding 33rd Annual General Meeting of the Company to be held through Video Conferencing / Other Audio Visual Means and Remote e-voting
2026-08-31 - Hexagon Nutrition Limited has informed the Exchange regarding Notice of undefined to be held on September 22, 2026
2026-08-26 - Hexagon Nutrition Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-19 - Hexagon Nutrition Limited has informed the Exchange regarding 'Disclosure Under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011, Ms. Anuradha Kelkar, Promoter group member of the Company acquired 15,000 Equity shares'.
2026-08-19 - Hexagon Nutrition Limited has informed the Exchange regarding 'Disclosure Under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011, Mr. Vikram Kelkar, Promoter and Managing Director of the Company acquired 16,300 Equity shares '.
2026-08-19 - Hexagon Nutrition Limited has informed the Exchange regarding 'Disclosure Under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011, this is to inform you that Dr. Nikhil Kelkar, Promoter and Joint Managing Director of the Company acquired 16,400 Equity shares '.
2026-08-18 - Hexagon Nutrition Limited has informed the Exchange about Transcript
News
Recent coverage and analyst commentary for HEXAGON
Loading news…
AI Stock Analyst
Hexagon Nutrition Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account

